Optimized protocol for induction of cytochrome P450 enzymes 1A2 and 3A4 in human primary-like hepatocyte cell strain HepaFH3 to study in vitro toxicology
Restricted accessResearch articleFirst published online February 22, 2019
Optimized protocol for induction of cytochrome P450 enzymes 1A2 and 3A4 in human primary-like hepatocyte cell strain HepaFH3 to study in vitro toxicology
Drug induced liver injury (DILI) is the most frequent cause for failure of new drugs in clinical studies. Thus, toxicity studies are indispensable during drug development. The proliferative human liver cell strain HepaFH3 with promising primary-like cellular properties might be a suitable liver model for such studies, but its cytochrome-P450 (CYP) expression is still in low ranges compared to freshly isolated primary human hepatocytes.
OBJECTIVE:
We aimed to optimize the induction protocol for CYP1A2 and CYP3A4 in HepaFH3 to obtain a physiologically relevant in vitro liver model.
METHODS:
CYP1A2 and CYP3A4 were induced by omeprazole and rifampicin, respectively. Induction of the two CYPs was measured by qRT-PCR, immunofluorescence and by P450 Glo enzyme activity assays.
RESULTS:
The optimized protocol made the experimental design six days shorter than the original procedure. CYP1A2 mRNA levels were induced 118-fold, CYP3A4 levels 36-fold. This result was also reflected at protein level. Enzymatic activity of CYP1A2 increased 3.7-fold and CYP3A4 activity increased 9.8-fold after induction.
CONCLUSIONS:
We succeeded in optimizing the induction protocol for HepaFH3 to such an extent that CYP1A2 and CYP3A4 are expressed in sufficient amounts that the cell strain can be used as a physiological relevant human liver model for in vitro toxicology studies.
SukKT, KimDJ. Drug-induced liver injury: Present and future. Clinical and Molecular Hepatology. 2012;18(3):249–57.
2.
RegevA. Drug-induced liver injury and drug development: Industry perspective. Semin Liver Dis. 2014;34(2):227–39.
3.
ChanR, BenetLZ. Evaluation of DILI Predictive Hypotheses in Early Drug Development. Chem Res Toxicol. 2017;30(4):1017–29.
4.
BjornssonE, OlssonR. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42(2):481–9.
5.
Robles-DiazM, LucenaMI, KaplowitzN, StephensC, Medina-CalizI, Gonzalez-JimenezA, et al. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology. 2014;147(1):109–18e5.
6.
KammererS, KüpperJH. Human hepatocyte systems for in vitro toxicology analysis. Journal of Cellular Biotechnology. 2018;in press.
7.
SteinbrechtS, KammererS, KüpperJH. HepG2 cell with recombinant cytochrome P450 enzyme overexpression: Their use and limitations as in vitro liver model. Journal of Cellular Biotechnology. 2018;in press.
8.
ArimotoR. Computational models for predicting interactions with cytochrome p450 enzyme. Current Topics in Medicinal Chemistry. 2006;6(15):1609–18.
9.
Gomez-LechonMJ, DonatoMT, CastellJV, JoverR. Human hepatocytes in primary culture: The choice to investigate drug metabolism in man. Current Drug Metabolism. 2004;5(5):443–62.
10.
VildhedeA, WisniewskiJR, NorenA, KarlgrenM, ArturssonP. Comparative Proteomic Analysis of Human Liver Tissue and Isolated Hepatocytes with a Focus on Proteins Determining Drug Exposure. Journal of Proteome Research. 2015;14(8):3305–14.
11.
ElautG, HenkensT, PapeleuP, SnykersS, VinkenM, VanhaeckeT, et al. Molecular mechanisms underlying the dedifferentiation process of isolated hepatocytes and their cultures. Current Drug Metabolism. 2006;7(6):629–60.
12.
ShimadaT, YamazakiH, MimuraM, InuiY, GuengerichFP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. The Journal of Pharmacology and Experimental Therapeutics. 1994;270(1):414–23.
13.
AdenDP, FogelA, PlotkinS, DamjanovI, KnowlesBB. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature. 1979;282(5739):615–6.
14.
BussoN, ChesneC, DelersF, MorelF, GuillouzoA. Transforming growth-factor-beta (TGF-beta) inhibits albumin synthesis in normal human hepatocytes and in hepatoma HepG2 cells. Biochemical and Biophysical Research Communications. 1990;171(2):647–54.
15.
MeierM, KleinHH, KramerJ, DrenckhanM, SchuttM. Calpain inhibition impairs glycogen syntheses in HepG2 hepatoma cells without altering insulin signaling. The Journal of Endocrinology. 2007;193(1):45–51.
16.
WesterinkWM, SchoonenWG. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicology in vitro: An international Journal Published in Association with BIBRA. 2007;21(8):1581–91.
17.
HerzogN, HansenM, MiethbauerS, SchmidtkeKU, AndererU, LuppA, et al. Primary-like human hepatocytes genetically engineered to obtain proliferation competence display hepatic differentiation characteristics in monolayer and organotypical spheroid cultures. Cell Biology International. 2016;40(3):341–53.
18.
BurkardA, DahnC, HeinzS, ZutavernA, Sonntag-BuckV, MaltmanD, et al. Generation of proliferating human hepatocytes using Upcyte(R) technology: Characterisation and applications in induction and cytotoxicity assays. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 2012;42(10):939–56.
19.
WrightonSA, SchuetzEG, ThummelKE, ShenDD, KorzekwaKR, WatkinsPB. The human CYP3A subfamily: Practical considerations. Drug Metabolism Reviews. 2000;32(3-4):339–61.
20.
HerzogN, KatzenbergerN, MartinF, SchmidtkeKU, KJh. Generation of cytochrome P450 3A4-overexpressing HepG2 cell clones for standardization of hepatocellular testosterone 6β-hydroxylation activity2015, pp. 15–26.
21.
MoscovitzJE, KalgutkarAS, NulickK, JohnsonN, LinZ, GoosenTC, et al. Establishing Transcriptional Signatures to Differentiate PXR-, CAR-, and AhR-Mediated Regulation of Drug Metabolism and Transport Genes in Cryopreserved Human Hepatocytes. The Journal of Pharmacology and Experimental Therapeutics. 2018;365(2):262–71.
22.
YoshinariK, UedaR, KusanoK, YoshimuraT, NagataK, YamazoeY. Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements. Biochemical Pharmacology. 2008;76(1):139–45.
23.
ShirasakaY, SagerJE, LutzJD, DavisC, IsoherranenN. Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions. Drug Metab Dispos. 2013;41(7):1414–24.
24.
NovotnaA, DvorakZ. Omeprazole and lansoprazole enantiomers induce CYP3A4 in human hepatocytes and cell lines via glucocorticoid receptor and pregnane X receptor axis. PloS one. 2014;9(8):e105580.
25.
KliewerSA, GoodwinB, WillsonTM. The nuclear pregnane X receptor: A key regulator of xenobiotic metabolism. Endocrine Reviews. 2002;23(5):687–702.
26.
LiT, ChiangJY. Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression. Drug metabolism and disposition: The biological Fate of Chemicals. 2006;34(5):756–64.
27.
BackmanJT, GranforsMT, NeuvonenPJ. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: Studies with tizanidine and caffeine. European Journal of Clinical Pharmacology. 2006;62(6):451–61.
28.
GeretsHHJ, TilmantK, GerinB, ChanteuxH, DepelchinBO, DhalluinS, et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biology and Toxicology. 2012;28(2):69–87.
29.
GramignoliR, TahanV, DorkoK, VenkataramananR, FoxIJ, EllisECS, et al. Rapid and Sensitive Assessment of Human Hepatocyte Functions. Cell Transplantation. 2014;23(12):1545–56.
